Oxford Biomedica PLC Logo

Oxford Biomedica PLC

A global CDMO specializing in cell and gene therapy and viral vector manufacturing.

OXB | IL

Overview

Corporate Details

ISIN(s):
GB00BDFBVT43
LEI:
213800S1GVQNXQ15K851
Country:
United Kingdom
Address:
WINDRUSH COURT, OX4 6LT OXFORD

Description

Oxford Biomedica (OXB) is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. A pioneer in the field, the company has extensive experience in viral vectors, the enabling technology for many advanced therapies. OXB provides end-to-end services to pharmaceutical and biotechnology partners, supporting programs from preclinical development through to commercial launch. Its core expertise includes the development and GMP manufacturing of various vector types, including lentivirus, adeno-associated virus (AAV), and adenovirus. The company offers proprietary technologies like its LentiVector™ platform, the first commercially approved lentiviral system, and its inAAVate™ platform for AAV, in addition to tech-transfer capabilities.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-06-23 17:31
2023 AGM minutes and resolutions
English 519.9 KB
2023-06-06 16:59
Total Voting Rights
English 10.0 KB
2023-05-15 08:00
Oxford Biomedica launches TetraVecta system
English 10.5 KB
2023-05-10 08:00
Block listing Application
English 10.7 KB
2023-05-05 08:00
2023 AGM Notification
English 7.8 KB
2023-05-05 06:52
Notice of 2023 AGM
English 326.3 KB
2023-05-02 08:00
Total Voting Rights
English 10.5 KB
2023-04-28 08:59
2022 Annual Report and Accounts
English 8.1 KB
2023-04-28 07:49
Annual financial and audit reports
English 26.8 MB
2023-04-28 07:49
Annual financial and audit reports
English 38.5 MB
2023-04-26 08:00
Board Appointment
English 10.4 KB
2023-04-25 08:00
Preliminary results for the year ended 31 Dec 2022
English 701.4 KB
2023-04-19 19:26
2022 Preliminary results revised date
English 8.3 KB
2023-04-03 14:19
Total Voting Rights
English 10.3 KB
2023-03-30 08:00
Notice of Preliminary Results
English 9.2 KB

Automate Your Workflow. Get a real-time feed of all Oxford Biomedica PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Oxford Biomedica PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Oxford Biomedica PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.